Skip to main content
OpenTrials
Completed

NCT Number: NCT03863379

Sarcopenic Obesity in Neurodisabilities

To describe the frequency and thresholds for sarcopenic obesity in neurodisabled persons and the fat and lean mass distribution based on various neurodisabilities

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenic Obesity Atrophy Autoimmune Diseases Autoimmune Diseases of the Nervous System Brain Diseases Brain Injuries Brain Injuries, Traumatic Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Craniocerebral Trauma Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Multiple Sclerosis Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Sarcopenia Signs and Symptoms Spinal Cord Diseases Spinal Cord Injuries Stroke Trauma, Nervous System Traumatic Brain Injury Vascular Diseases Wounds and Injuries

Age range

20 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Rehabilitation Center EKA

Nea Liosia, Athens, 13122, Greece

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Persons with

  • stroke / cerebrovascular disease
  • traumatic brain injury
  • multiple sclerosis
  • spinal cord injuries (including spinal cord lesions i.e. myelopathies etc.)

Exclusion criteria

Persons with

  • heterotopic ossifications,
  • chronic administration of drugs, which promote fat increase
  • chronic administration of drugs, which promote bone or muscle loss
  • co-existing other diseases such as: endocrinopathies, muscular dystrophies, non-alcoholic fatty liver disease.

Treatment and study plan

whole body DXA

Diagnostic Test

Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.

Primary outcomes

  1. Fat and lean mass in neurodisabled

    Time frame: an average of 1 year

  2. Frequency of sarcopenic obesity

    Time frame: an average of 1 year

Secondary outcomes

  1. Body mass index correlation with fat mass and visceral fat

    Time frame: an average of 1 year

Sponsors and collaborators

Lead sponsor

Dionyssiotis, Yannis, M.D.

Indiv

Collaborators

  • University of Athens
  • University of Patras

Registry information

Official study title

Sarcopenic Obesity in Neurodisabled People

Acronym: SarcObeNDS

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Mar 5, 2019
Registry last updated
Jan 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.